Patents Assigned to Institut de Recherches Cliniques de Montreal
-
Publication number: 20230293624Abstract: The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2 a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.Type: ApplicationFiled: February 10, 2022Publication date: September 21, 2023Applicants: Cornell Research Foundation, Inc., Institut De Recherches Cliniques De MontrealInventors: Hazel H. Szeto, Peter W. Schiller, Kesheng Zhao
-
Publication number: 20200038472Abstract: The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2 a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.Type: ApplicationFiled: September 12, 2019Publication date: February 6, 2020Applicants: Cornell Research Foundation, Inc., Institut De Recherches Cliniques de MontrealInventors: Hazel H. Szeto, Peter W. Schiller, Kesheng Zhao
-
Publication number: 20170008925Abstract: The disclosure provides aromatic-cationic peptide compositions and methods of preventing or treating disease using the same. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.Type: ApplicationFiled: February 11, 2016Publication date: January 12, 2017Applicants: Cornell University, Institut de Recherches Cliniques de MontrealInventors: Hazel H. SZETO, Peter W. SCHILLER
-
Publication number: 20150005242Abstract: The disclosure provides aromatic-cationic peptide compositions and methods of preventing or treating disease using the same. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.Type: ApplicationFiled: September 16, 2014Publication date: January 1, 2015Applicants: Institut de Recherches Cliniques de Montreal, Cornell UniversityInventors: Hazel H. SZETO, Peter W. SCHILLER
-
Publication number: 20140079713Abstract: A method for modulating Sonic hedgehog (Shh)-mediated signalling and proliferation based on agents that modulates the binding of GAS1, BOC and/or CDON to Ptch1 is disclosed. Methods and compositions for treating cancer using agents that inhibit the binding of GAS1, BOC and/or CDON to Ptch1 are also disclosed. Methods for identifying agents that may be used to inhibit Shh-mediated signalling/proliferation and cancer based on their capacity to inhibit the binding of GAS1, BOC and/or CDON to Ptch1 are also disclosed.Type: ApplicationFiled: May 2, 2012Publication date: March 20, 2014Applicant: INSTITUT DE RECHERCHES CLINIQUES DE MONTREALInventors: Frederic Charron, Luisa Izzi, Steves Morin
-
Patent number: 8673850Abstract: A method for identifying a compound for preventing or treating a LDLR-associated disease, a VLDLR-associated disease or an ApoER2-associated disease, said method comprising determining whether: a) a level of expression of Annexin A2 nucleic acid or encoded polypeptide; b) a level of Annexin A2 activity; or c) a combination of a) and b), is increased in the presence of a test compound relative to in the absence of said test compound, wherein said increase is indicative that said test compound can be used for preventing or treating a LDLR-associated disease, a VLDLR-associated disease, an ApoER2-associated disease.Type: GrantFiled: June 1, 2009Date of Patent: March 18, 2014Assignee: Institut de Recherches Cliniques de MontrealInventors: Nabil G. Seidah, Gaétan Mayer, Steve Poirier
-
Publication number: 20130316964Abstract: The disclosure provides aromatic-cationic peptide compositions and methods of preventing or treating disease using the same. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.Type: ApplicationFiled: August 7, 2013Publication date: November 28, 2013Applicants: INSTITUT DE RECHERCHES CLINIQUES DE MONTREAL, CORNELL UNIVERSITYInventors: Hazel H. SZETO, Peter W. SCHILLER
-
Publication number: 20130149311Abstract: Methods, uses and kits for increasing the number of hematopoietic stem cells (HSCs) in a biological system, such as for increasing the number of HSCs in the bone marrow and/or blood of a subject, based on the modulation of growth factor independence 1b (Gfi1b), are disclosed.Type: ApplicationFiled: May 6, 2011Publication date: June 13, 2013Applicant: INSTITUT DE RECHERCHES CLINIQUES DE MONTREALInventors: Tarik Moroy, Cyrus Khandanpour, Lothar Vassen, Ehssan Sharif-Askari
-
Patent number: 8404646Abstract: The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2 a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.Type: GrantFiled: September 28, 2011Date of Patent: March 26, 2013Assignees: Cornell Research Foundation, Inc., Institut de Recherches Cliniques de MontrealInventors: Peter W. Schiller, Hazel H. Szeto, Kesheng Zhao
-
Patent number: 8361988Abstract: The present invention comprises compounds useful as antiviral or antitumor agents. The compounds comprise nucleotide analogues that comprise tetrahydrofuranyl or tetrahydrothienyl moeities with quaternary centers at the 3? position. The nucleotide analogues can be used to inhibit cancer or viruses. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting diseases or conditions associated with cancers and viruses. Thus, the present invention also comprising pharmaceutical formulations comprising the compounds and methods of using the compounds and formulations to inhibit viruses or tumors and treat, prevent, or inhibit the foregoing diseases.Type: GrantFiled: January 17, 2008Date of Patent: January 29, 2013Assignee: Institut de Recherches Cliniques de MontrealInventor: Yvan Guindon
-
Patent number: 8241846Abstract: Methods, uses, agents and compositions useful for the diagnosis, prevention and/or treatment of invasive diseases such as cancer based on the modulation of the expression and/or activity of brother of CDON (BOC) are disclosed.Type: GrantFiled: September 8, 2009Date of Patent: August 14, 2012Assignees: Institut de Recherches Cliniques de Montreal, The Hospital for Sick ChildrenInventors: Frédéric Charron, Cynthia Hawkins, Martin Lévesque
-
Patent number: 8088571Abstract: A method for treating and/or preventing a proprotein convertase subtilisin/kexin type 9 preproprotein (PCSK9)-susceptible viral infection comprising increasing a PCSK9 activity and/or expression in a biological system infected by the virus, whereby the increased PCSK9 activity and/or expression treats and/or prevents the viral infection in the biological system. Methods of classifying subjects, methods of screening and kits therefore.Type: GrantFiled: September 19, 2008Date of Patent: January 3, 2012Assignees: Institut de Recherches Cliniques de Montreal, Institut National de la Recherche ScientifiqueInventors: Nabil G. Seidah, Patrick Labonté
-
Publication number: 20110092451Abstract: The present invention comprises compounds useful as antiviral or antitumor agents. The compounds comprise nucleotide analogues that comprise tetrahydrofuranyl or tetrahydrothienyl moeities with quaternary centers at the 3? position. The nucleotide analogues can be used to inhibit cancer or viruses. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting diseases or conditions associated with cancers and viruses. Thus, the present invention also comprising pharmaceutical formulations comprising the compounds and methods of using the compounds and formulations to inhibit viruses or tumors and treat, prevent, or inhibit the foregoing diseases.Type: ApplicationFiled: March 18, 2009Publication date: April 21, 2011Applicant: INSTITUT DE RECHERCHES CLINIQUES DE MONTREALInventor: Yvan Guindon
-
Publication number: 20110003315Abstract: A chimera protein comprising in the following order: a signal peptide, a proprotein convertase subtilisin/kexin type 9 preproprotein (PCSK9) sequence consisting of amino acid residues at positions 35 to 696 of SEQ ID NO: 38, a transmembrane domain and a cytosolic domain, wherein said cytosolic (CT) domain comprises a sequence able to recycle the protein from the cellular membrane to endosomes.Type: ApplicationFiled: May 8, 2007Publication date: January 6, 2011Applicant: INSTITUT DE RECHERCHES CLINIQUES DE MONTREALInventors: Nabil G. Seidah, Jean Davignon, Geneviève Dubuc, Lise Bernier, Michel Tremblay
-
Publication number: 20100093737Abstract: The present invention comprises compounds useful as antiviral or antitumor agents. The compounds comprise nucleotide analogues that comprise tetrahydrofuranyl or tetrahydrothienyl moeities with quaternary centers at the 3? position. The nucleotide analogues can be used to inhibit cancer or viruses. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting diseases or conditions associated with cancers and viruses. Thus, the present invention also comprising pharmaceutical formulations comprising the compounds and methods of using the compounds and formulations to inhibit viruses or tumors and treat, prevent, or inhibit the foregoing diseases.Type: ApplicationFiled: January 17, 2008Publication date: April 15, 2010Applicant: INSTITUT DE RECHERCHES CLINIQUES DE MONTREALInventor: Yvan Guindon
-
Publication number: 20100015654Abstract: The present invention relates to the identification EAT-2 and ERT as novel therapeutic targets for the modulation of innate immune cell functions. More particularly the present invention describes novel methods for modulating innate immune cells-mediated immune response, useful in the treatment of cancer, infectious diseases as well as autoimmune diseases.Type: ApplicationFiled: May 15, 2006Publication date: January 21, 2010Applicant: Institut De Recherches Cliniques De Montreal/ I.R.C.M.Inventors: Andre Veillette, Romain Roncagalli
-
Publication number: 20090130691Abstract: A chimeric protein comprising in sequence a signal peptide, a first amino acid tag, a proteinase bait, a second amino acid tag, a transmembrane domain and a cytosolic domain, wherein the cytosolic (CT) domain comprises a sequence able to recycle the protein from the cellular membrane to endosomes. A cell line expressing the chimeric protein and an assay using the cell line.Type: ApplicationFiled: September 14, 2006Publication date: May 21, 2009Applicant: Institut de Recherches Cliniques de MontrealInventors: Nabil Seidah, Timothy L. Reudelhuber
-
Patent number: 7446189Abstract: Improved vaccines and methods of using the same are disclosed Immunosuppressive compositions for treating individuals who have autoimmune diseases or transplants and methods of using the same are disclosed.Type: GrantFiled: April 27, 2000Date of Patent: November 4, 2008Assignees: Institut de Recherches Cliniques de Montreal, The Trustees of the University of Pennsylvania, Valorisation-Recherche, Societe en CommanditeInventors: David B. Weiner, Michael G. Agadjanyan, Rafick P. Sekaly, Mark Holterman
-
Mammalian Subtilisin/kexin isozyme SKI-1: a proprotein convertase with a unique cleavage specificity
Patent number: 7211424Abstract: Using RT-PCR and degenerate oligonucleotides derived from the active site residues of subtilisin-kexin-like serine proteinases, we have identified a highly conserved and phylogenetically ancestral human, rat and mouse type-I membrane-bound proteinase called subtilisin-kexin-isozyme-1 (SKI-1). Computer data bank searches reveals that human SKI-1 was previously cloned but with no identified function. A SKI-1 processed fragment is secreted in culture media in a soluble form. In vitro studies suggest that SKI-1 is a Ca2+-dependent serine proteinase exhibiting a wide pH optimum for cleavage of proBDNF. Peptides mimicking SKI-1 cleavages sites are also disclosed. SKI-1 prosegment has an ex vivo inhibitory effect on SKI-1 activity. The prosegment is also processed and secreted in culture media. One of its fragments is found tightly associated with the SKI-1 soluble form. Therapeutic applications for SKI-1 inhibitors are disclosed.Type: GrantFiled: November 4, 1999Date of Patent: May 1, 2007Assignee: Institut de Recherches Cliniques de MontrealInventors: Nabil G. Seidah, Michel Chretien, Mieczyslaw Marcinkiewicz -
Patent number: 6852538Abstract: The present invention relates to intracellular receptors, and methods for the modulation of transcription using same. More particularly, the invention relates to the Nur family of nuclear receptors. In general aspects, the present invention relates to the idenfication of a physiologically relevant response element (RE) for Nur family members, an ER-10 element as well as to the idenfication of the type of protein-protein interactions of Nur family member, enabling their specific interaction with this RE-10 and tfeir modulation of transcription at physiologically relevant sites. The invention further relates to methods for modulating processes mediated by such nuclear receptors.Type: GrantFiled: December 12, 1997Date of Patent: February 8, 2005Assignee: Institut de Recherches Cliniques de MontrealInventors: Jacques Drouin, Alexandra Philips, Mario Maira